Data from a 55-patient study in the American Society for Artificial Internal Organs Journal showed positive results for Abiomed's Impella 5.5 with SmartAssist heart pump in the US. "This report demonstrates the benefit of unloading cardiogenic shock patients, and it is encouraging to see real-world data demonstrate improved survival rates with use of Impella 5.5 with SmartAssist," said Danny Ramzy, Cedars-Sinai Medical Center's director of robotic and minimally invasive surgery.

An offering of approximately 37.3 million shares of common stock is expected to bring in $13 million in proceeds for TransEnterix. The offering, closing on or around July 6, includes a 45-day option for underwriters to buy almost 5.6 million more shares.

Preliminary results from a study by University of Virginia School of Medicine researchers showed that a blood test was able to help identify which patients with new coronavirus infections would need a ventilator. The findings, which have not been peer-reviewed, have been reported on the website medRxiv.

Eurofins has launched the INgezim dual-recognition immunochromatographic assays, which are finger-prick point-of-care testing devices that can deliver results within 10 minutes and identify previous exposure to COVID-19. The tests have received CE mark approval.

The Mariner Outrigger and Mariner MIS spinal fixation systems have been released by SeaSpine. The Mariner Outrigger improves surgical flow in revision spinal fusions, while the Mariner MIS is used to correct sagittal balance and stabilize hybrid constructs.

The compliance date for unique device identifier requirements for Class I devices, unclassified medical devices and certain other devices has been extended by the FDA to Sept. 24, 2022.

The FDA, under a supplemental marketing application, has granted Axonics Modulation Technologies 3T full-body MRI conditional labeling for its Axonics r-SNM System.

The FDA has given emergency use authorization to Kroger for its COVID-19 Test Home Collection Kit that will allow people to perform nasal swab sample collections on their own with the virtual supervision of a health care provider.

European regulators have given CE mark approval to KDx Diagnostics for its URO17 Bladder Cancer Recurrence test.

Novartis agreed to pay $678 million to settle allegations that it paid kickbacks to physicians through sham speaker fees to boost prescriptions of its diabetes and cardiovascular drugs. Separately, the company agreed to pay $51.25 million to resolve accusations that it violated the False Claims Act by funneling money through three charitable foundations to cover cost sharing for Medicare patients taking its drugs.